Request Demo

Last update 08 May 2025

Dalfopristin mesilate

Last update 08 May 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Dalfopristin

Target

50S subunit

Action

inhibitors

Mechanism

50S subunit inhibitors(50S ribosomal subunit inhibitors)

Therapeutic Areas

Infectious Diseases

Active Indication

Gram-Negative Bacterial InfectionsGram-Positive Bacterial Infections

Inactive Indication-

Originator Organization-

Active Organization-

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date-

Regulation-

Structure/Sequence

Molecular FormulaC34H50N4O9S

InChIKeySUYRLXYYZQTJHF-VMBLUXKRSA-N

CAS Registry112362-50-2

100 Clinical Results associated with Dalfopristin mesilate

100 Translational Medicine associated with Dalfopristin mesilate

100 Patents (Medical) associated with Dalfopristin mesilate

1,504

Literatures (Medical) associated with Dalfopristin mesilate

01 Apr 2025·Infection, Disease & Health

Bacterial bloodstream infections in a pediatric population: A 7-year experience at a tertiary care center in Saudi Arabia

Article

Author: Alghamdi, Salem ; Hussain, Ibrahim Bin ; Alyabes, Ohoud ; Alrshaid, Bandar ; Aljumaah, Suliman ; Albanyan, Esam ; Basnawi, Faten ; Alshuhri, Sabah ; Alhajjar, Sami ; Essa, Ruba Abo ; Alosaimi, Aeshah ; Almazrua, Afnan ; Alsuhaibani, Mohammed

OBJECTIVESThis study explored the epidemiological trends and antimicrobial susceptibility patterns of bloodstream pathogens among pediatric patients over a 7-year period at a tertiary care facility in Saudi Arabia.METHODSThis retrospective single-center longitudinal descriptive study was conducted from 2015 to 2021. Blood culture and susceptibility data of pathogens isolated from patients aged <15 years were extracted from the hospital's laboratory information system. The trends observed over the 7-year period were graphically illustrated.RESULTSAmong the 83,605 pediatric blood cultures analyzed, 2945 (3.5 %) tested positive. Approximately 65 % of the positive cultures were confirmed as true bloodstream infections (BSIs), with an average BSI rate of 3 per 1000 inpatient days. Gram-negative bacterial infections accounted for 61 % of BSIs, with Klebsiella spp. being the most prevalent. Susceptibility testing revealed reduced sensitivity to meropenem, imipenem, ciprofloxacin, and levofloxacin among gram-negative bacteria. Gram-positive pathogens represented 39 % of infections, with the most common being Staphylococcus spp. (21 %) and Streptococcus spp. (7 %). Methicillin-resistant Staphylococcus aureus exhibited 100 % sensitivity to vancomycin, quinupristin/dalfopristin, tigecycline, and linezolid. However, Streptococcus pneumoniae showed decreasing sensitivity to penicillin and ceftriaxone for meningitis (33 % and 55 % susceptibility, respectively). Furthermore, Enterococcus spp. were less susceptible against ampicillin, linezolid, levofloxacin, and vancomycin.CONCLUSIONSThe findings of this study offer crucial insights into the incidence of pediatric bacteremia and trends in antibiotic susceptibility, which can inform treatment strategies, guide antibiotic stewardship programs, and enhance infection control measures in healthcare settings.

01 Sep 2024·Indian Journal of Microbiology

Prevalence and Antibiotic Resistance Patterns of Methicillin-Resistant Staphylococcus aureus (MRSA) in a Hospital Setting: A Retrospective Study from 2018 to 2022

Article

Author: Lan, Tian ; Wen, Hong Mei ; Jia, Qian ; Xu, Yu Huan ; Gao, Jing ; Yan, Juan ; Liu, Jin Lu ; Xie, Xiao Juan ; Zhang, Bin ; Cao, Liang ; Li, Bao Liang

Methicillin-resistant Staphylococcus aureus (MRSA) is a highly infectious pathogen that poses a serious threat to human life and health. This study aimed to provide a scientific basis for the rational clinical use of antimicrobial drugs for treating MRSA infections and inform the development of preventive and control measures by analyzing the clinical distribution and resistance characteristics of MRSA in a hospital in Hebei China. To accomplish this, bacterial identification and drug sensitivity experiments were performed with 1858 Staphylococcus aureus (S. aureus) strains collected from a hospital from January 2018 to December 2022 using a phoenixTM-100 bacterial identification drug sensitivity analyzer. The experimental data were analyzed using WHONET 5.6 software, and the MRSA strains detected were analyzed for their clinical distribution and drug resistance. Of the 1858 S. aureus strains isolated, 429 were MRSA. Sputum samples had the highest MRSA detection rates (52.45%). Critical care medicine had the highest rate of MRSA (12.59%), followed by dermatology (9.79%). MRSA resistance to tetracycline increased by 13.9% over 5 years; resistance to quinupristin/dalfopristin also increased but remained low (1.9%). Resistance decreased to gentamicin, rifampicin, ciprofloxacin, and cotrimoxazole, though most significantly to erythromycin and clindamycin, exceeding 77% and 83%, respectively. No strains were resistant to vancomycin, teicoplanin, or linezolid, and drug resistance was most prevalent in patients ≥ 60 years old. This study will aid in improving the diagnosis and treatment of MRSA infections.

01 Jul 2024·Diagnostic Microbiology and Infectious Disease

16S rRNA female reproductive microbiome investigation reveals Dalfopristin, Clorgyline, and Hydrazine as potential therapeutics for the treatment of bacterial vaginosis

Article

Author: Dua, Riya ; Narad, Priyanka ; Redhu, Ritu ; Kulshrestha, Sudeepti ; Gupta, Payal ; Gupta, Romasha ; Gupta, Somesh ; Sengupta, Abhishek

Bacterial vaginosis (BV) is a prevalent vaginal illness resulting from a disruption in the vaginal microbial equilibrium. The vaginal microbiota has been shown to have a substantial impact on the development and continuation of BV. This work utilized 16S rRNA sequence analysis of vaginal microbiome samples (Control vs BV samples) utilizing Parallel-Meta 3 to investigate the variations in microbial composition. The unique genes identified were used to determine prospective therapeutic targets and their corresponding inhibitory ligands. Further, molecular docking was conducted and then MD simulations were carried out to confirm the docking outcomes. In the BV samples, we detected several anaerobic bacteria recognized for their ability to generate biofilms, namely Acetohalobium, Anaerolineaceae, Desulfobacteraceae, and others. Furthermore, we identified Dalfopristin, Clorgyline, and Hydrazine as potential therapeutic options for the management of BV. This research provides new insights into the causes of BV and shows the potential effectiveness of novel pharmacological treatments.

100 Deals associated with Dalfopristin mesilate

External Link

KEGG	Wiki	ATC	Drug Bank
-	Dalfopristin mesilate	J01FG	DB01764

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Gram-Negative Bacterial Infections	-	-	-
Gram-Positive Bacterial Infections	-	-	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis